Corcept Therapeutics: Q3 Earnings Insights

Shares of Corcept Therapeutics CORT fell 4.49% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 22.58% over the past year to $0.24, which beat the estimate of $0.20.

Revenue of $86,327,000 rose by 5.92% year over year, which missed the estimate of $90,870,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 03, 2020

Time: 05:00 PM

ET Webcast URL: https://ir.corcept.com/events/event-details/corcept-therapeutics-q3-2020-earnings-conference-call

Recent Stock Performance

Company's 52-week high was at $23.48

Company's 52-week low was at $9.70

Price action over last quarter: Up 23.96%

Company Description

Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.